{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:15:32Z","timestamp":1791533732465,"version":"4.3.4"},"reference-count":60,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022434","name":"Walloon excellence in life sciences and biotechnology","doi-asserted-by":"publisher","award":["WELBIO CR-2015A-07"],"award-info":[{"award-number":["WELBIO CR-2015A-07"]}],"id":[{"id":"10.13039\/501100022434","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FNRS-T\u00e9l\u00e9vie","award":["7.4597.18"],"award-info":[{"award-number":["7.4597.18"]}]},{"name":"FNRS-T\u00e9l\u00e9vie","award":["7. 4501.15F"],"award-info":[{"award-number":["7. 4501.15F"]}]},{"DOI":"10.13039\/501100013845","name":"Foundation against cancer","doi-asserted-by":"crossref","award":["2014-137"],"award-info":[{"award-number":["2014-137"]}],"id":[{"id":"10.13039\/501100013845","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013845","name":"Foundation against cancer","doi-asserted-by":"crossref","award":["2019-092"],"award-info":[{"award-number":["2019-092"]}],"id":[{"id":"10.13039\/501100013845","id-type":"DOI","asserted-by":"crossref"}]},{"name":"WALinnov grant from the Walloon region","award":["IMMUCAN 1610119"],"award-info":[{"award-number":["IMMUCAN 1610119"]}]},{"name":"Fonds de la Recherche Scientific","award":["FRS-FNRS, EOS O000518F"],"award-info":[{"award-number":["FRS-FNRS, EOS O000518F"]}]},{"name":"FRS-FNRS- charg\u00e9 de recherches","award":["FC-7929"],"award-info":[{"award-number":["FC-7929"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,3,30]]},"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite their revolutionary success in cancer treatment over the last decades, immunotherapies encounter limitations in certain tumor types and patients. The efficacy of immunotherapies depends on tumor antigen-specific CD8 T-cell viability and functionality within the immunosuppressive tumor microenvironment, where oxygen levels are often low. Hypoxia can reduce CD8 T-cell fitness in several ways and CD8 T cells are mostly excluded from hypoxic tumor regions. Given the challenges to achieve durable reduction of hypoxia in the clinic, ameliorating CD8 T-cell survival and effector function in hypoxic condition could improve tumor response to immunotherapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Activated CD8 T cells were exposed to hypoxia and metformin and analyzed by fluorescence-activated cell sorting for cell proliferation, apoptosis and phenotype. In vivo, metformin was administered to mice bearing hypoxic tumors and receiving either adoptive cell therapy with tumor-specific CD8 T cells, or immune checkpoint inhibitors; tumor growth was followed over time and CD8 T-cell infiltration, survival and localization in normoxic or hypoxic tumor regions were assessed by flow cytometry and immunofluorescence. Tumor oxygenation and hypoxia were measured by electron paramagnetic resonance and pimonidazole staining, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found that the antidiabetic drug metformin directly improved CD8 T-cell fitness in hypoxia, both in vitro and in vivo. Metformin rescued murine and human CD8 T cells from hypoxia-induced apoptosis and increased their proliferation and cytokine production, while blunting the upregulation of programmed cell death protein 1 and lymphocyte-activation gene 3. This appeared to result from a reduced production of reactive oxygen species, due to the inhibition of mitochondrial complex I. Differently from what others reported, metformin did not reduce tumor hypoxia, but rather increased CD8 T-cell infiltration and survival in hypoxic tumor areas, and synergized with cyclophosphamide to enhance tumor response to adoptive cell therapy or immune checkpoint blockade in different tumor models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study describes a novel mechanism of action of metformin and presents a promising strategy to achieve immune rejection in hypoxic and immunosuppressive tumors, which would otherwise be resistant to immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2022-005719","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T10:10:27Z","timestamp":1683281427000},"page":"e005719","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":113,"title":["Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression"],"prefix":"10.1136","volume":"11","author":[{"given":"Veronica","family":"Finisguerra","sequence":"first","affiliation":[{"name":"de Duve Institute, UCLouvain, Brussels, Belgium"},{"name":"Ludwig Institute for Cancer Research, de Duve Institute, Brussels, Belgium"},{"name":"Walloon Excellence in Life Science and Biotechnology (WELBIO), WEL Research Institute, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Dvorakova","sequence":"additional","affiliation":[{"name":"de Duve Institute, UCLouvain, Brussels, Belgium"},{"name":"Ludwig Institute for Cancer Research, de Duve Institute, Brussels, Belgium"},{"name":"Walloon Excellence in Life Science and Biotechnology (WELBIO), WEL Research Institute, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Formenti","sequence":"additional","affiliation":[{"name":"de Duve Institute, UCLouvain, Brussels, Belgium"},{"name":"Ludwig Institute for Cancer Research, de Duve Institute, Brussels, Belgium"},{"name":"Walloon Excellence in Life Science and Biotechnology (WELBIO), WEL Research Institute, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Van Meerbeeck","sequence":"additional","affiliation":[{"name":"de Duve Institute, UCLouvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9426-8600","authenticated-orcid":false,"given":"Lionel","family":"Mignion","sequence":"additional","affiliation":[{"name":"Biomedical Magnetic Resonance (REMA) Group, Louvain Drug Research Institute, UCLouvain, Brussels, Belgium"},{"name":"Nuclear and Electron Spin Technologies (NEST) Platform, Louvain Drug Research Institute, UCLouvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Gallez","sequence":"additional","affiliation":[{"name":"Biomedical Magnetic Resonance (REMA) Group, Louvain Drug Research Institute, UCLouvain, Brussels, Belgium"},{"name":"Nuclear and Electron Spin Technologies (NEST) Platform, Louvain Drug Research Institute, UCLouvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4995-3270","authenticated-orcid":false,"given":"Benoit J","family":"Van den Eynde","sequence":"additional","affiliation":[{"name":"de Duve Institute, UCLouvain, Brussels, Belgium"},{"name":"Ludwig Institute for Cancer Research, de Duve Institute, Brussels, Belgium"},{"name":"Walloon Excellence in Life Science and Biotechnology (WELBIO), WEL Research Institute, Brussels, Belgium"},{"name":"Nuffield Department of Clinical Medicine, Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"2025100306412825000_11.5.e005719.1","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41416-021-01413-x","article-title":"Cancer immunotherapy: it\u2019s time to better predict patients\u2019 response","volume":"125","author":"Pilard","year":"2021","journal-title":"Br J Cancer"},{"key":"2025100306412825000_11.5.e005719.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3455"},{"key":"2025100306412825000_11.5.e005719.3","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s13402-021-00602-3","article-title":"Angiogenesis as a hallmark of solid tumors-clinical perspectives","volume":"44","author":"Majidpoor","year":"2021","journal-title":"Cell Oncol (Dordr)"},{"key":"2025100306412825000_11.5.e005719.4","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.121"},{"key":"2025100306412825000_11.5.e005719.5","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00018.2019"},{"key":"2025100306412825000_11.5.e005719.6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00032","article-title":"Starved and asphyxiated: how can CD8(+) T cells within a tumor microenvironment prevent tumor progression","volume":"7","author":"Zhang","year":"2016","journal-title":"Front Immunol"},{"key":"2025100306412825000_11.5.e005719.7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187314","article-title":"Hypoxia and hypoxia-inducible factor (HIF) downregulate antigen-presenting MHC class I molecules limiting tumor cell recognition by T cells","volume":"12","author":"Sethumadhavan","year":"2017","journal-title":"PLoS One"},{"key":"2025100306412825000_11.5.e005719.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.11.007"},{"key":"2025100306412825000_11.5.e005719.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.10.003"},{"key":"2025100306412825000_11.5.e005719.10","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143729","article-title":"Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells","volume":"131","author":"Liikanen","year":"2021","journal-title":"J Clin Invest"},{"key":"2025100306412825000_11.5.e005719.11","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa1260","article-title":"Immunological mechanisms of the antitumor effects of supplemental oxygenation","volume":"7","author":"Hatfield","year":"2015","journal-title":"Sci Transl Med"},{"key":"2025100306412825000_11.5.e005719.12","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2015.02.009"},{"key":"2025100306412825000_11.5.e005719.13","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S200059"},{"key":"2025100306412825000_11.5.e005719.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117717"},{"key":"2025100306412825000_11.5.e005719.15","doi-asserted-by":"publisher","DOI":"10.1093\/abbs\/gmx106"},{"key":"2025100306412825000_11.5.e005719.16","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0103"},{"key":"2025100306412825000_11.5.e005719.17","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41590-020-00860-7","article-title":"Tumor hypoxia represses \u03b3\u03b4 T cell-mediated antitumor immunity against brain tumors","volume":"22","author":"Park","year":"2021","journal-title":"Nat Immunol"},{"key":"2025100306412825000_11.5.e005719.18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1417636112"},{"key":"2025100306412825000_11.5.e005719.19","doi-asserted-by":"publisher","DOI":"10.1038\/nature08097"},{"key":"2025100306412825000_11.5.e005719.20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002614","article-title":"Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy","volume":"9","author":"Munoz","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100306412825000_11.5.e005719.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2018.07.030"},{"key":"2025100306412825000_11.5.e005719.22","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1442167","article-title":"Metformin blocks myeloid-derived suppressor cell accumulation through AMPK-DACH1-CXCL1 axis","volume":"7","author":"Qin","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100306412825000_11.5.e005719.23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2460"},{"key":"2025100306412825000_11.5.e005719.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0666-9"},{"key":"2025100306412825000_11.5.e005719.25","first-page":"800","article-title":"Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer","volume":"9","author":"Han","year":"2019","journal-title":"Am J Cancer Res"},{"key":"2025100306412825000_11.5.e005719.26","first-page":"6965","article-title":"Metformin attenuates PD-L1 expression through activating Hippo signaling pathway in colorectal cancer cells","volume":"11","author":"Zhang","year":"2019","journal-title":"Am J Transl Res"},{"key":"2025100306412825000_11.5.e005719.27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1787"},{"key":"2025100306412825000_11.5.e005719.28","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19095-z","article-title":"Metformin enhances anti-mycobacterial responses by educating CD8+ T-cell immunometabolic circuits","volume":"11","author":"B\u00f6hme","year":"2020","journal-title":"Nat Commun"},{"key":"2025100306412825000_11.5.e005719.29","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3216"},{"key":"2025100306412825000_11.5.e005719.30","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-00784-1","article-title":"Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes","volume":"8","author":"Zhu","year":"2017","journal-title":"Nat Commun"},{"key":"2025100306412825000_11.5.e005719.31","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-4354"},{"key":"2025100306412825000_11.5.e005719.32","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.50740","article-title":"Preclinical murine tumor models: a structural and functional perspective","volume":"9","author":"Guerin","year":"2020","journal-title":"Elife"},{"key":"2025100306412825000_11.5.e005719.33","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-011-0245-0"},{"key":"2025100306412825000_11.5.e005719.34","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0391-1","article-title":"Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option","volume":"6","author":"Rohaan","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2025100306412825000_11.5.e005719.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2009.05.004"},{"key":"2025100306412825000_11.5.e005719.36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01834","article-title":"Rewiring mitochondrial metabolism for CD8+ T cell memory formation and effective cancer immunotherapy","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol"},{"key":"2025100306412825000_11.5.e005719.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.08.009"},{"key":"2025100306412825000_11.5.e005719.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0793-3"},{"key":"2025100306412825000_11.5.e005719.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-00834-9"},{"key":"2025100306412825000_11.5.e005719.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2012.12.001"},{"key":"2025100306412825000_11.5.e005719.41","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.freeradbiomed.2016.11.014","article-title":"Sestrin2 inhibits hypoxia-inducible factor-1\u03b1 accumulation via AMPK-mediated prolyl hydroxylase regulation","volume":"101","author":"Seo","year":"2016","journal-title":"Free Radic Biol Med"},{"key":"2025100306412825000_11.5.e005719.42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0900465106"},{"key":"2025100306412825000_11.5.e005719.43","doi-asserted-by":"crossref","first-page":"100787","DOI":"10.1016\/j.drup.2021.100787","article-title":"Hypoxia as a driver of resistance to immunotherapy","volume":"59","author":"Kopecka","year":"2021","journal-title":"Drug Resist Updat"},{"key":"2025100306412825000_11.5.e005719.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.02.065"},{"key":"2025100306412825000_11.5.e005719.45","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.02242","article-title":"Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis","volume":"3","author":"Wheaton","year":"2014","journal-title":"Elife"},{"key":"2025100306412825000_11.5.e005719.46","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124989","article-title":"Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma","volume":"4","author":"Najjar","year":"2019","journal-title":"JCI Insight"},{"key":"2025100306412825000_11.5.e005719.47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165214","article-title":"MATE2 expression is associated with cancer cell response to metformin","volume":"11","author":"Chowdhury","year":"2016","journal-title":"PLoS One"},{"key":"2025100306412825000_11.5.e005719.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2015.03.017"},{"key":"2025100306412825000_11.5.e005719.49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2007.05686.x"},{"key":"2025100306412825000_11.5.e005719.50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007033","article-title":"Oxygen consumption can regulate the growth of tumors, a new perspective on the Warburg effect","volume":"4","author":"Chen","year":"2009","journal-title":"PLoS One"},{"key":"2025100306412825000_11.5.e005719.51","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002954","article-title":"Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2\/mTORC1\/p62 axis in tumor-infiltrating CD8T lymphocytes","volume":"9","author":"Nishida","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100306412825000_11.5.e005719.52","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2016.23"},{"key":"2025100306412825000_11.5.e005719.53","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0915174107"},{"key":"2025100306412825000_11.5.e005719.54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-237412"},{"key":"2025100306412825000_11.5.e005719.55","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25863"},{"key":"2025100306412825000_11.5.e005719.56","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000350","article-title":"Beyond DNA damage: exploring the immunomodulatory effects of cyclophosphamide in multiple myeloma","volume":"4","author":"Swan","year":"2020","journal-title":"Hemasphere"},{"key":"2025100306412825000_11.5.e005719.57","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in car T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"2025100306412825000_11.5.e005719.58","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.molonc.2011.03.007","article-title":"Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12","volume":"5","author":"Malvicini","year":"2011","journal-title":"Mol Oncol"},{"key":"2025100306412825000_11.5.e005719.59","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001483"},{"key":"2025100306412825000_11.5.e005719.60","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-3596"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-005719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:41:37Z","timestamp":1759498897000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":60,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,5]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1136\/jitc-2022-005719"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-005719","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}